Clinical Trial Update: Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the safety and efficacy of serplulimab plus chemotherapy in small-cell lung cancer that has transformed from EGFR-mutated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Small-cell Lung Cancer | Phase 2 | Status: RECRUITING